Year: 2026
Type: article
Abstract: Recent advances in Alzheimer’s disease research have reshaped how clinical trials are designed and interpreted, particularly through the use of targeted monoclonal antibodies, biomarker-guided enrollment, and novel drug delivery strategies. Evidence from recent clinical and translational studies highlights a growing gap between biological target engagement and meaningful improvements in cognition, functional independence, and quality of life. Although emerging therapies demonstrate measurable effects on disease biology, their clinical impact remains modest and inconsistent. Ensuring that mechanistic innovation aligns with patient-centered outcomes will be essential for translating these advances into meaningful therapeutic progress.
Author: Rachel Sudhakar
Institution: University of Ottawa
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7159980437
FWCI:
Cites:
Cited by:
Related to: